CN107669991A - A kind of pharmaceutical composition for reducing serum uric acid level and preparation method thereof - Google Patents
A kind of pharmaceutical composition for reducing serum uric acid level and preparation method thereof Download PDFInfo
- Publication number
- CN107669991A CN107669991A CN201711193599.5A CN201711193599A CN107669991A CN 107669991 A CN107669991 A CN 107669991A CN 201711193599 A CN201711193599 A CN 201711193599A CN 107669991 A CN107669991 A CN 107669991A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- uric acid
- acid level
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/754—Evodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a kind of pharmaceutical composition for reducing serum uric acid level, it is by being prepared comprising the bulk drug that following weight matches：17 23 parts of cassia twig, 17 23 parts of turmeric, 17 23 parts of the root of fangji, 17 23 parts of plantain seed, 7 13 parts of edible tulip, 12 18 parts of evodia rutaecarpa.Present invention also offers the preparation method of said composition and purposes.Composition provided by the invention, compatibility is reasonable, and to reducing serum uric acid level significant effect, available for treatment hyperuricemia, urarthritis, a kind of new medicament selection is provided for clinic.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for being used to reduce serum uric acid level and its production and use.
Background technology
Uric acid is the final product of internal purine metabolism, is mainly discharged by kidney, when concentration of the uric acid level in blood surpasses
Normal value is crossed, uric acid now is easily deposited on soft tissue or raw acute inflammation reaction is triggered in joint, causes hyperuricemia, gout
Deng.
With the improvement of people ' s living standards and dietary structure change, the Excess free enthalpy of high purine food, make purine
Metabolism gets muddled, and uric acid in blood increases, and the incidence that result in global gout and hyperuricemia shows becoming for growth
Gesture.Data show that China's gout and the hyperuricemia incidence of disease are significantly risen with 7.5% speed every year, China's gout and
Hyperuricemia number of the infected is up to 13,500,000 people, and for wherein patient's course of disease more than 10 years, the overwhelming majority was difficult to what is cured
Uremia, its harm can't neglect.
The pathogenesis of gout and hyperuricemia is not completely clear and definite yet so far, and in treatment, doctor trained in Western medicine also only stops at present
Improve symptom using medicine and control uric acid level, such as colchicin, NSAIDs, glucocorticoid medicine, still
Have not been able to effect a radical cure hyperuricemia, gout, and easily cause the adverse events such as serious gastrointestinal reaction, influence treatment and carry out.
In recent years, herbal treatment has been increasingly becoming with the features such as its treatment method is various, evident in efficacy, adverse reaction is lacked
Treat the development trend of gout.With Basic Theories of Chinese Medicine, active development produces with evident in efficacy, safe and reliable antigout is introduced
Product, the direction that numerous medical personals make great efforts.
The content of the invention
It is an object of the invention to provide a kind of pharmaceutical composition for reducing serum uric acid level and its production and use.
The invention provides a kind of pharmaceutical composition for reducing serum uric acid level, it is the original by being matched comprising following weight
Material medicine is prepared：
Cassia twig 17-23 parts, turmeric 17-23 parts, root of fangji 17-23 parts, plantain seed 17-23 parts, edible tulip 7-13 parts, evodia rutaecarpa
12-18 parts.
Wherein, it is prepared by the raw material of following weight proportioning：
20 parts of cassia twig, 20 parts of turmeric, 20 parts of the root of fangji, 20 parts of plantain seed, 10 parts of edible tulip, 15 parts of evodia rutaecarpa.
Wherein, it be by cassia twig, turmeric, the root of fangji, plantain seed, edible tulip, evodia rutaecarpa primary powder or water or organic solvent
Extract is active component, adds the preparation that pharmaceutically acceptable auxiliary material or complementary composition are prepared.
Wherein, the preparation is oral formulations.
Wherein, the oral formulations are decoction, paste, oral liquid, granule, capsule, pill, tablet, powder.
Present invention also offers the preparation method of above-mentioned composition, and it comprises the following steps：
A, the raw material of each weight proportion is weighed；
Raw material directly beaten to powder, or after adding water or organic solvent extraction, add pharmaceutically acceptable auxiliary material or auxiliary b,
Property composition is prepared.
Present invention also offers purposes of the above-mentioned composition in the medicine for reducing serum uric acid level is prepared.
Wherein, the medicine for reducing serum uric acid level is the medicine for treating hyperuricemia and/or gout.
Wherein, the medicine of the treatment gout is the medicine for the treatment of urarthritis.
Present invention also offers purposes of the above-mentioned composition in the medicine for preparing treatment traditional Chinese medical science syndrome of accumulated dampness-heat.
The traditional Chinese medical science thinks that hyperuricemia causes endogenous damp formation due to native endowment (being mostly the body of plump phlegm wet) more, then
Plus drink, the product of addiction delicious food savoury, cause it is wet it is turbid more very, change thermalization poison, the stagnant internal resistance of the stasis of blood, close and stay in passages through which vital energy circulates joint, then joint
Congestion and swelling pain；Long person, raw stasis of blood life phlegm, joint deformity, very skin subcutaneous nodule, then diabrosis, seepage fat.The reduction serum uric acid level
The analgesic of Stephania tetrandra clearing heat and promoting diuresis is monarch in pharmaceutical composition；Chinese herbaceous peony benevolence clearing heat and promoting diuresis eliminating impediment, evodia rutaecarpa analgesic, dehumidifying blood-arthralgia are
Minister；Turmeric promoting blood circulation and stopping pain, edible tulip clearing heat and eliminating phlegm, softening and resolving hard mass, cassia twig degrading the channel, sharp joint make for assistant.Heat-clearing is played altogether in full side
Sharp turbid, blood circulation promoting and dispersing pathogen accumulation, the work(of eliminating impediment and relieving pain.It is that event hyperuricemia and all diseases of urarthritis must solve.
Composition provided by the invention, compatibility is reasonable, can significantly reduce serum uric acid level, available for treating antihyperuricemic
Disease, urarthritis, evident in efficacy to improving clinical symptoms, pain of alleviation, clinical cure rate is good；And the present composition
Security is good, has no toxic side effect, easy to use, and a kind of new medicament selection is provided for clinic.
Obviously, according to the above of the present invention, according to the ordinary technical knowledge and customary means of this area, do not departing from
Under the premise of the above-mentioned basic fundamental thought of the present invention, the modification, replacement or change of other diversified forms can also be made.
The embodiment of form by the following examples, the above of the present invention is remake further specifically
It is bright.But the scope that this should not be interpreted as to the above-mentioned theme of the present invention is only limitted to following example.It is all to be based on the above of the present invention
The technology realized belongs to the scope of the present invention.
Embodiment
It is described further below with embodiment, but the present invention is not limited to these embodiments.
The preparation of the present composition of embodiment 1
Prescription：Cassia twig 20g, turmeric 20g, root of fangji 20g, plantain seed 20g, edible tulip 10g, evodia rutaecarpa 15g.
Preparation technology：
(1) each bulk drug is weighed by prescription；
(2) first step：First medicinal material is put into marmite, adds 2000ml water, soaks half an hour.Second step：With force
After fiery (big fire) boils, then surplus 300ml boiled with slow fire (small fire), well-done decoction is poured out in bowl.3rd step：It is repeatable
First (can not soak), two steps, front and rear mixing twice are taken.
The preparation of the present composition of embodiment 2
Prescription：Cassia twig 17g, turmeric 17g, root of fangji 23g, plantain seed 23g, edible tulip 13g, evodia rutaecarpa 18g.
Preparation technology：With the preparation technology of embodiment 1.
The preparation of the present composition of embodiment 3
Prescription：Cassia twig 23g, turmeric 23g, root of fangji 17g, plantain seed 17g, edible tulip 7g, evodia rutaecarpa 12g.
Preparation technology：With the preparation technology of embodiment 1.
The preparation of the present composition of embodiment 4
Prescription：With the prescription of embodiment 1.
Preparation technology：Each bulk drug is weighed by prescription, is crushed, is sieved, is well mixed, packing, is produced.
Illustrate beneficial effects of the present invention with the mode of test example below：
The present composition of test example 1 reduces the clinical observation of serum uric acid level
First, case source
In January, 2010 in August, 2017 is gone to a doctor in Hospital Affiliated To Chengdu Traditional Chinese Medicine Univ out-patient, according to random controls
Table is grouped at random.
2nd, diagnostic criteria
1. primary gout diagnosis that Western medicine diagnostic criteria was formulated using rheumatology branch of Chinese Medical Association in 2010 and
Diagnostic criteria (the primary gouts diagnosis of rheumatology branch of Chinese Medical Association and treatment guidelines [J], the Chinese wind for the treatment of guidelines
Diseases caused by dampness magazine, 2011,15 (6):410-413)；
2. TCM syndrome diagnostic criteria uses version in 2012《Chinese medical disease criterion of therapeutical effect》Middle gout (damp-heat accumulation) is examined
Disconnected standard (State Administration of Traditional Chinese Medicine Chinese medical diseases Standardization of diagnosis and curative effect [S], Beijing:China Medical Science Press, 2012:
50-51)。
3rd, case selection standard
1. inclusive criteria:1. meet the Western medicine diagnostic criteria of gout；2. meet the diagnostic criteria of traditional Chinese medical science syndrome of accumulated dampness-heat.
2. exclusion standard:1. patient used glucocorticoid treatment in one week；2. patient because with digestive tract ulcer,
The patient of the contraindication of the non-steroidal drugs such as adverse cardiac；3. pregnant woman or the patient of nursing period women；4. prepare fertility in the recent period
Patient；5. mental patient.
4th, treatment method
By random packet, it is divided into control group and treatment group, treats respectively as follows：
Control group：Colchicin 0.5mg, orally, 3 times a day.
Treatment group：Cassia twig 20g turmeric 20g root of fangji 20g plantain seed 20g edible tulip 10g evodia rutaecarpa 15g, are decocted in water for oral dose (i.e.：Press
According to the preparation technology of the embodiment of the present invention 1), one portion per day.
The course for the treatment of is 2 months.
Five, curative effect index
1. serum uric acid gathers limosis vein blood censorship, blood uric acid is checked.
2. clinical efficacy clinic control：The symptom such as redness and swelling of joints and pain disappears, joint can normal activity, integration reduces big
In equal to 95%.It is effective：The symptom such as redness and swelling of joints and pain disappears substantially, and joint motion is unrestricted, and integration reduction 70%~
94%.Effectively：The symptom such as redness and swelling of joints and pain improves, and joint motion slightly limits, and integration reduces 30%~69%.It is invalid：
For the symptom such as redness and swelling of joints and pain with joint motion without improvement, integration, which is reduced, is less than 30%.
3. Observation of pain index wherein arthralgia uses visual analogue scales (Visual Analogue Scale/
Score, abbreviation VAS)：It is divided into 0-10 points.0 point：It is painless；Less than 3 points：There is slight pain, patient can endure；4-6 points：Patient
Pain simultaneously influences to sleep, and can still endure；7 points -10 points：Patient has strong pain, in great pain.
6th, data analysis
Software analysis, enumeration data Chi-square Test are counted with SPSS 13.0, measurement data is examined with t, and P ＜ 0.05 are poor
It is different statistically significant.
7th, treatment results
The pretherapy and post-treatment serum uric acid level of 1 patient compares
It is shown in Table 1.
Table 1：Patient's serum uric acid level compares (mmol/L)
| Group | Number of cases | Before treatment | After treatment |
| Treatment group | 40 | 523.9±34.2 | 412.7±29.9*# |
| Control group | 38 | 529±39.5 | 435.4±30.8* |
Note：Compared with before treatment, * P ＜ 0.05；Compared with after control group treatment, #P ＜ 0.05
From table 1, compared with before treatment, uric acid level significantly reduces after 2 groups of patient's treatments, and difference is statistically significant
(P<0.05), illustrate that pharmaceutical composition of the present invention and positive drug can reduce serum uric acid level；
Compared with after control group treatment, uric acid level significantly reduces after treatment group's treatment, the statistically significant (P of difference<
0.05), illustrate that the significant effect of pharmaceutical composition reduction serum uric acid level of the present invention is better than positive control colchicin.
2 two groups of Clinical efficacy comparisons
It is shown in Table 2.
Table 2：Two groups of curative effects compare (%)
| Group | Number of cases | It is effective | Effectively | It is invalid |
| Treatment group | 40 | 23 | 17 | 0 |
| Control group | 38 | 17 | 19 | 2 |
Note：Compared with control group, P ＜ 0.05
From table 2, the total effective rate for the treatment of group is 100%, and therapeutic effect is notable, and compared with control group, difference has system
Meter learns meaning (P ＜ 0.05).
The contrast of the pretherapy and post-treatment VAS scorings of 3 patients
It is shown in Table 3.
Table 3：Patient VAS scorings are compared
| Group | Number of cases | Before treatment | After treatment |
| Treatment group | 40 | 7.8±0.3 | 2.5±0.1*# |
| Control group | 38 | 8.0±0.4 | 3.1±0.2* |
Note：Compared with before treatment, * P ＜ 0.05；Compared with after control group treatment, #P ＜ 0.05
From table 3, VAS, which scores, compared with before treatment, after 2 groups of patient's treatments significantly reduces the statistically significant (P of difference
<0.05), illustrating two groups has therapeutic effect；
Compared with after control group treatment, VAS scores and significantly reduced after treatment group's treatment, the statistically significant (P of difference<
0.05), illustrate that pharmaceutical composition of the present invention is better compared with control group in terms of patient pain is mitigated.
Therefore, the present composition can significantly reduce serum uric acid level, improve patient clinical symptom, reduction of patient arthritis
Bitterly, illustrate that pharmaceutical composition of the present invention can effectively treat gout and hyperuricemia, particularly acute gout arthritis is imitated
Fruit is obvious, and the effect of medicine of the present invention reduction serum uric acid level is better than comparison medicine colchicin.
To sum up, present composition compatibility is reasonable, can significantly reduce serum uric acid level, available for treating antihyperuricemic
Disease, urarthritis, evident in efficacy to improving clinical symptoms, pain of alleviation, clinical effective rate is good；And the present composition
Security is good, has no toxic side effect, easy to use, and a kind of new medicament selection is provided for clinic.
Claims (10)
- A kind of 1. pharmaceutical composition for reducing serum uric acid level, it is characterised in that：It is the raw material by being matched comprising following weight Medicine is prepared：Cassia twig 17-23 parts, turmeric 17-23 parts, root of fangji 17-23 parts, plantain seed 17-23 parts, edible tulip 7-13 parts, evodia rutaecarpa 12- 18 parts.
- 2. pharmaceutical composition according to claim 1, it is characterised in that：It is by following weight proportioning raw material prepare and Into：20 parts of cassia twig, 20 parts of turmeric, 20 parts of the root of fangji, 20 parts of plantain seed, 10 parts of edible tulip, 15 parts of evodia rutaecarpa.
- 3. composition according to claim 1 or 2, it is characterised in that：It is by cassia twig, turmeric, the root of fangji, plantain seed, mountain Arrowhead, the primary powder or water or extractive with organic solvent of evodia rutaecarpa are active component, add pharmaceutically acceptable auxiliary material or auxiliary The preparation that helping property composition is prepared.
- 4. composition according to claim 3, it is characterised in that：The preparation is oral formulations.
- 5. composition according to claim 4, it is characterised in that：The oral formulations be decoction, paste, oral liquid, Granula, capsule, pill, tablet, powder.
- 6. the preparation method of the composition described in claim 1-5 any one, it is characterised in that：It comprises the following steps：A, the raw material of each weight proportion is weighed；Raw material directly beaten to powder, or after adding water or organic solvent extraction b, add pharmaceutically acceptable auxiliary material or it is complementary into Divide and be prepared.
- 7. purposes of the composition in the medicine for reducing serum uric acid level is prepared described in claim 1-5 any one.
- 8. purposes according to claim 7, it is characterised in that：The medicine for reducing serum uric acid level is treatment high lithemia The medicine of mass formed by blood stasis and/or gout.
- 9. purposes according to claim 8, it is characterised in that：The medicine of the treatment gout is treatment urarthritis Medicine.
- 10. purposes of the composition in the medicine for preparing treatment traditional Chinese medical science syndrome of accumulated dampness-heat described in claim 1-5 any one.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711193599.5A CN107669991B (en) | 2017-11-24 | 2017-11-24 | Pharmaceutical composition for reducing blood uric acid level and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711193599.5A CN107669991B (en) | 2017-11-24 | 2017-11-24 | Pharmaceutical composition for reducing blood uric acid level and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107669991A true CN107669991A (en) | 2018-02-09 |
| CN107669991B CN107669991B (en) | 2020-11-06 |
Family
ID=61149915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711193599.5A Active CN107669991B (en) | 2017-11-24 | 2017-11-24 | Pharmaceutical composition for reducing blood uric acid level and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107669991B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111773352A (en) * | 2019-09-20 | 2020-10-16 | 厦门医学院 | Application of turmeric and plantain seed composition in preparation of pharmaceutical composition for reducing blood sugar and blood pressure |
| CN112843178A (en) * | 2021-03-04 | 2021-05-28 | 刘树民 | Compatible combination for treating hyperuricemia and preparation method thereof |
| CN113144095A (en) * | 2020-01-07 | 2021-07-23 | 成都医学院 | Pharmaceutical composition for treating gouty arthritis and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101264205A (en) * | 2008-04-25 | 2008-09-17 | 北京中泰天和科技有限公司 | Chinese medicinal composition for treating gout and preparation thereof |
| CN103721125A (en) * | 2014-01-21 | 2014-04-16 | 李朝成 | Medicament for treating gout and preparation method thereof |
-
2017
- 2017-11-24 CN CN201711193599.5A patent/CN107669991B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101264205A (en) * | 2008-04-25 | 2008-09-17 | 北京中泰天和科技有限公司 | Chinese medicinal composition for treating gout and preparation thereof |
| CN103721125A (en) * | 2014-01-21 | 2014-04-16 | 李朝成 | Medicament for treating gout and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 黄德军: "加减木防己汤治疗痛风性关节炎40例报告", 《中医正骨》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111773352A (en) * | 2019-09-20 | 2020-10-16 | 厦门医学院 | Application of turmeric and plantain seed composition in preparation of pharmaceutical composition for reducing blood sugar and blood pressure |
| CN113144095A (en) * | 2020-01-07 | 2021-07-23 | 成都医学院 | Pharmaceutical composition for treating gouty arthritis and preparation method and application thereof |
| CN113144095B (en) * | 2020-01-07 | 2022-08-02 | 成都医学院 | Pharmaceutical composition for treating gouty arthritis and preparation method and application thereof |
| CN112843178A (en) * | 2021-03-04 | 2021-05-28 | 刘树民 | Compatible combination for treating hyperuricemia and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107669991B (en) | 2020-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102813801B (en) | Traditional Tibetan medicine for treating cough and preparation method thereof | |
| CN102441081B (en) | Medicament for treating gout and its preparation method | |
| WO2006076844A1 (en) | Traditional chinese medicament for treating injuries from falls, rheumatism and ostealgia and method for manufacture thereof | |
| CN107669991A (en) | A kind of pharmaceutical composition for reducing serum uric acid level and preparation method thereof | |
| CN102423423A (en) | Traditional Chinese medicine for treating urinary tract infection | |
| CN101991811B (en) | Traditional Chinese medicine composition for treating rheumatism arthralgia, cold headache, abdominal cavity pain and chilblain and preparation method thereof | |
| CN101032598B (en) | Expectorant cough suppressant and anti-asthmatic healthy wine | |
| CN103768357B (en) | A kind of Traditional Chinese medicine compound composition with treatment recurrent aphtha | |
| CN104706953A (en) | Traditional Chinese medicine preparation for treating chronic cervicitis | |
| CN105998558B (en) | A kind of Chinese medicine composition and preparation method thereof for treating primary biliary cirrhosis | |
| CN104225016B (en) | A kind of pharmaceutical composition treating due to weakness of spleen and stomach chronic atrophic gastritis | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN102178759A (en) | Traditional Chinese medicine composition for treating rheumatism and preparation method of composition | |
| CN101947290A (en) | Medicament with yin-nourishing effect | |
| CN105194355A (en) | Traditional Chinese medicine preparation for treating primary hypertension | |
| CN104306948A (en) | Medicament composition for treating gouty arthritis | |
| CN105982906A (en) | Application of 20(R)-ginsenoside Rg3 in preparing medicines or health products capable of alleviating or/and treating rheumatoid diseases and medicines | |
| CN103463401B (en) | Asthma medicine for infants | |
| CN103463402B (en) | Traditional Chinese medicine composition for infantile asthma and preparation method thereof | |
| CN101385810B (en) | Traditional Chinese medicine composition containing chinemys reevesii for treating dermatomyositis and preparation thereof | |
| CN104055886A (en) | Medicinal composition for treating chronic cough, and preparation method and application thereof | |
| CN105796886A (en) | Pharmaceutical composition capable of treating chronic constipation | |
| CN103463403B (en) | Pharmaceutical composition for infantile asthma | |
| CN105687499A (en) | Betaxolol containing pharmaceutical composition for treating hypertension and preparation method thereof | |
| CN105194352A (en) | Traditional Chinese medicine composition capable of improving learning and memory abilities and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |